Meda passes Xerese and Elidel on to Valeant in NAFTA for $76 million plus royalties
This article was originally published in Scrip
Following yesterday's news that Medivir is selling rights to the cold sore treatment Xerese in the US, Canada and Mexico to Meda for $45 million, Meda has confirmed it is in turn selling the Xerese rights, along with North American rights to the atopic dermatitis treatment Elidel, to Valeant Pharmaceuticals.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.